CLN-619 is under clinical development by Cullinan Oncology and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CLN-619’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CLN-619 is under development for the treatment of solid tumors such as Non-small cell lung cancer, cervical cancer, head and neck cancer squamous cell carcinoma, colon cancer, prostate cancer and metastatic urothelial carcinoma. The therapeutic candidate is a anti-MICA humanized IgG1 monoclonal antibody and acts by targeting MHC class I polypeptide related sequence A (MICA) and MHC class I polypeptide related sequence B (MICB). It is administered by intravenous route.
It was also under development for liver cancer.
Cullinan Oncology overview
Cullinan Oncology (Cullinan) clinical-stage biopharmaceutical company that specializes in identifying and advancing drug candidates through preclinical and clinical stages. The company discover and developed therapeutics to treat cancer. Cullinan pipeline product portfolio includes CLN-081, CLN-049, CLN-619, CLN-978, CLN-617 and CLN-418. The company offers its products in the therapeutic area for the treatment of non-small cell lung cancer, acute myeloid leukemia, cancer, solid tumors and advanced malignancies, among others. It works in collaboration with other Pharmaceutical companies for drug discovery and development. Cullinan is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of CLN-619’s drug-specific PTSR and LoA scores, buy the report here.